Skandinaviska Enskilda Banken Ab (Publ) Kymera Therapeutics, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.5 Billion
- Q3 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 38,141 shares of KYMR stock, worth $1.6 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
38,141
Previous 38,141
-0.0%
Holding current value
$1.6 Million
Previous $1.14 Million
58.61%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding KYMR
# of Institutions
184Shares Held
64.4MCall Options Held
50.6KPut Options Held
81.7K-
Price T Rowe Associates Inc Baltimore, MD6.65MShares$279 Million0.04% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$252 Million3.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$217 Million7.77% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$205 Million28.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.75MShares$199 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.3B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...